FDA Greenlights Glaukos’ Breakthrough Eye Therapy for Corneal Disease
The U.S. Food & Drug Administration (FDA) has approved a new therapy from Glaukos Corporation, offering a less painful treatment for a rare eye condition called keratoconus. Keratoconus causes the cornea to thin and bulge, which leads to vision loss if untreated. Glaukos’ new topical therapy aims to treat this condition without the need for…